Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Q3 2025 value amounting to $113691.0.

  • Cumberland Pharmaceuticals' Change in Receivables rose 13677.68% to $113691.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$880023.0, marking a year-over-year increase of 853.47%. This contributed to the annual value of $1.9 million for FY2024, which is 15707.25% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Change in Receivables stood at $113691.0 for Q3 2025, which was up 13677.68% from -$171014.0 recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Change in Receivables peaked at $7.8 million during Q1 2022, and registered a low of -$3.4 million during Q2 2021.
  • For the 5-year period, Cumberland Pharmaceuticals' Change in Receivables averaged around -$111434.2, with its median value being -$171014.0 (2025).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Change in Receivables soared by 442145.25% in 2022, and later crashed by 66656.04% in 2024.
  • Cumberland Pharmaceuticals' Change in Receivables (Quarter) stood at -$3.0 million in 2021, then soared by 30.41% to -$2.1 million in 2022, then fell by 21.54% to -$2.5 million in 2023, then skyrocketed by 115.54% to $390841.0 in 2024, then tumbled by 70.91% to $113691.0 in 2025.
  • Its Change in Receivables was $113691.0 in Q3 2025, compared to -$171014.0 in Q2 2025 and -$1.2 million in Q1 2025.